Search Results

Mitigating infection risks: The promise and challenge of bispecific antibodies in haematological malignancies.

• Authors : Rafei H; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Rezvani K

Subjects: Antibodies, Bispecific*/Antibodies, Bispecific*/Antibodies, Bispecific*/therapeutic use ; Antibodies, Bispecific*/Antibodies, Bispecific*/Antibodies, Bispecific*/adverse effects ; Hematologic Neoplasms*/Hematologic Neoplasms*/Hematologic Neoplasms*/therapy

• Source: British journal of haematology [Br J Haematol] 2024 Sep; Vol. 205 (3), pp. 764-766. Date of Electronic Publication: 2024 Jul 22.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium:

Record details

Bispecific Antibodies, Immune Checkpoint Inhibitors, and Antibody-Drug Conjugates Directing Antitumor Immune Responses: Challenges and Prospects.

• Authors : Li CL; Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Ma XY

Subjects: Antibodies, Bispecific*/Antibodies, Bispecific*/Antibodies, Bispecific*/therapeutic use ; Antibodies, Bispecific*/Antibodies, Bispecific*/Antibodies, Bispecific*/pharmacology ; Antibodies, Bispecific*/Antibodies, Bispecific*/Antibodies, Bispecific*/immunology

• Source: Cell biochemistry and function [Cell Biochem Funct] 2024 Dec; Vol. 42 (8), pp. e70011.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8305874 Publication Model: Print Cited Medium:

Record details

B-cell maturation antigen-directed bispecific antibodies in plasmablastic lymphoma.

• Authors : Hofer KD; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.; Wolfensberger N

Subjects: Antibodies, Bispecific*/Antibodies, Bispecific*/Antibodies, Bispecific*/therapeutic use ; Plasmablastic Lymphoma*/Plasmablastic Lymphoma*/Plasmablastic Lymphoma*/drug therapy ; Plasmablastic Lymphoma*/Plasmablastic Lymphoma*/Plasmablastic Lymphoma*/pathology

• Source: British journal of haematology [Br J Haematol] 2024 Aug; Vol. 205 (2), pp. 722-725. Date of Electronic Publication: 2024 May 23.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium:

Record details

Utilizing targeted integration CHO pools to potentially accelerate the GMP manufacturing of monoclonal and bispecific antibodies.

• Authors : Barnard GC; Cell Culture and Bioprocess Operations, Genentech, South San Francisco, California, USA.; Zhou M

Subjects: Antibodies, Bispecific*/Antibodies, Bispecific*/Antibodies, Bispecific*/genetics; Cricetinae ; Animals

• Source: Biotechnology progress [Biotechnol Prog] 2024 Jan-Feb; Vol. 40 (1), pp. e3399. Date of Electronic Publication: 2023 Oct 24.Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 8506292 Publication Model: Print-Electronic Cited

Record details

The evolving therapy of DLBCL: Bispecific antibodies.

• Authors : Hutchings M; Department of Haematology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark.

Subjects: Antibodies, Bispecific*/Antibodies, Bispecific*/Antibodies, Bispecific*/therapeutic use ; Lymphoma, B-Cell*/Lymphoma, B-Cell*/Lymphoma, B-Cell*/pathology ; Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/drug therapy

• Source: Hematological oncology [Hematol Oncol] 2023 Jun; Vol. 41 (S1), pp. 107-111.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8307268 Publication Model: Print Cited Medium:

Record details

Applied Science & Technology Full Text (H.W. Wilson)

Record details

Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.

• Authors : Lakshman A; Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Subjects: Antibodies, Bispecific/Antibodies, Bispecific/Antibodies, Bispecific/*therapeutic use ; Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/*therapeutic use ; Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/*therapeutic use

• Source: American journal of hematology [Am J Hematol] 2022 Jan 01; Vol. 97 (1), pp. 99-118. Date of Electronic Publication: 2021 Nov 10.Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited

Record details

Risk‐adapted treatment in multiple myeloma: Does more make it merrier?

• Authors : Zanwar, Saurabh¹ (AUTHOR); Galarza Fortuna, Gliceida M.² (AUTHOR); Sborov, Douglas W.² (AUTHOR)

Subjects: *BISPECIFIC antibodies; *FLUORESCENCE in situ hybridization; *CHIMERIC antigen receptors

• Source: British Journal of Haematology. Sep2024, Vol. 205 Issue 3, p767-769. 3p.

Record details

The state of the art of bispecific antibodies for treating human malignancies.

• Authors : Wang S; Clinical Cancer Center/National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.; Chen K

Subjects: Antibodies, Bispecific*/Antibodies, Bispecific*/Antibodies, Bispecific*/therapeutic use ; Neoplasms*/Neoplasms*/Neoplasms*/drug therapy; Antigens

• Source: EMBO molecular medicine [EMBO Mol Med] 2021 Sep 07; Vol. 13 (9), pp. e14291. Date of Electronic Publication: 2021 Aug 24.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101487380 Publication Model: Print-Electronic Cited

Record details

Bispecific antibodies for the treatment of lymphomas: Promises and challenges.

• Authors : Schuster SJ; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennyslvania, USA.; Lymphoma Program & Lymphoma Translational Research, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennyslvania, USA.

Subjects: Antibodies, Bispecific/Antibodies, Bispecific/Antibodies, Bispecific/*therapeutic use ; Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/*therapeutic use ; Lymphoma, B-Cell/Lymphoma, B-Cell/Lymphoma, B-Cell/*drug therapy

• Source: Hematological oncology [Hematol Oncol] 2021 Jun; Vol. 39 Suppl 1, pp. 113-116.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8307268 Publication Model: Print Cited Medium:

Record details